ENTYVIO (also known as Vedolizumab)
Mechanism:
Entyvio is an antibody that binds to a gut-specific cell adhesion molecule / integrin and thereby reduces gut-specific inflammation.
Indications:
Contraindications:
Patients with active infection should not be started on Entyvio.
Administration:
Entyvio is typically administered as an infusion over thirty minutes and repeated at week 2, 6, and every 8 weeks thereafter.